2022
DOI: 10.1016/j.mbplus.2022.100108
|View full text |Cite|
|
Sign up to set email alerts
|

Small molecule inhibitors of mammalian glycosylation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
4
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 14 publications
(4 citation statements)
references
References 345 publications
0
4
0
Order By: Relevance
“…To further evaluate the performance of the setup using a more challenging sample, we imaged the glycocalyx: a complex meshwork of cell-surface glycans that are vital for various cellular processes ( Figure 3 C). 51 Until recently, imaging the glycocalyx with high spatial resolution remained a challenging task owing to the lack of appropriate tools to specifically label the glycocalyx and due to its height, which is below the diffraction limit. Here, we combine metabolic labeling of sialic acid residues with super-resolution microscopy as described earlier.…”
Section: Resultsmentioning
confidence: 99%
“…To further evaluate the performance of the setup using a more challenging sample, we imaged the glycocalyx: a complex meshwork of cell-surface glycans that are vital for various cellular processes ( Figure 3 C). 51 Until recently, imaging the glycocalyx with high spatial resolution remained a challenging task owing to the lack of appropriate tools to specifically label the glycocalyx and due to its height, which is below the diffraction limit. Here, we combine metabolic labeling of sialic acid residues with super-resolution microscopy as described earlier.…”
Section: Resultsmentioning
confidence: 99%
“…Therapeutic strategies to protect and restore the glycocalyx and its downstream functions are also highlighted in several of the manuscripts included in this special issue. In the review by Almahayni et al, a comprehensive overview of small molecule inhibitors of glycosylation is presented [14] . Although many of these inhibitors currently have limitations and exhibit cytotoxic effects, it may in the future be possible to use these inhibitors strategically to diminish the impact of aberrant glycosylation within the glycocalyx that can occur during disease progression.…”
Section: Glycocalyx Repairmentioning
confidence: 99%
“…Another inhibitor is SGN-2FF which is fucosylation inhibitor but the clinical trial with these has been terminated due to adverse effects (ClinicalTrials.gov Identifier: NCT02952989). Further review article includes sialidase inhibitor, Sialyltransferase inhibitor, Fucosylation inhibitor on lung cancer cell lines [119] .…”
Section: Therapeutic Approach For Targeting Ptm In Nsclcmentioning
confidence: 99%